GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orchestra BioMed Holdings Inc (NAS:OBIO) » Definitions » Inventory Turnover

Orchestra BioMed Holdings (Orchestra BioMed Holdings) Inventory Turnover : 0.26 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Orchestra BioMed Holdings Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Orchestra BioMed Holdings's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.03 Mil. Orchestra BioMed Holdings's Average Total Inventories for the quarter that ended in Mar. 2024 was $0.13 Mil. Orchestra BioMed Holdings's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.26.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Orchestra BioMed Holdings's Days Inventory for the three months ended in Mar. 2024 was 350.24.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Orchestra BioMed Holdings's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.21.

Orchestra BioMed Holdings Inventory Turnover Historical Data

The historical data trend for Orchestra BioMed Holdings's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orchestra BioMed Holdings Inventory Turnover Chart

Orchestra BioMed Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Inventory Turnover
2.10 2.91 1.23 0.88

Orchestra BioMed Holdings Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.26 0.26 0.33 0.26

Orchestra BioMed Holdings Inventory Turnover Calculation

Orchestra BioMed Holdings's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Inventory Turnover (A: Dec. 2023 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2023 ) / ((Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count )
=0.186 / ((0.276 + 0.146) / 2 )
=0.186 / 0.211
=0.88

Orchestra BioMed Holdings's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover (Q: Mar. 2024 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Mar. 2024 ) / ((Total Inventories (Q: Dec. 2023 ) + Total Inventories (Q: Mar. 2024 )) / count )
=0.034 / ((0.146 + 0.115) / 2 )
=0.034 / 0.1305
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orchestra BioMed Holdings  (NAS:OBIO) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Orchestra BioMed Holdings's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory =Average Total Inventories (Q: Mar. 2024 )/Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=0.1305/0.034*365 / 4
=350.24

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Orchestra BioMed Holdings's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=0.1305 / 0.62
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Orchestra BioMed Holdings Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Orchestra BioMed Holdings's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Orchestra BioMed Holdings (Orchestra BioMed Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orchestra BioMed Holdings Inc (NAS:OBIO) » Definitions » Inventory Turnover
Comparable Companies
GRTS QSI BIVI GLUE AKBA ALLK OTLK ATXS TCRX IVVD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
150 Union Square Drive,, New Hope, PA, USA, 18938
Website
https://www.orchestrabiomed.com
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. Orchestra BioMed's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
Executives
George Papandreou officer: See Remarks C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Eric S Fain director ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN MN
Jason Aryeh director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
David P Hochman director, officer: See Remarks 15 WESTON HILL RD., RIVERSIDE CT 06878
Joshua Aiello officer: Principal Accounting Officer 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Yuval Mika officer: See Remarks 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Pamela Ann Connealy director 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Darren Sherman director, officer: See Remarks C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Rose Eric A Md director 161 FORT WASHINGTON AVENUE, 7TH FLOOR, NEW YORK NY 10032
Andrew Lawrence Taylor officer: Chief Financial Officer C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
William Reed Little officer: See Remarks C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Plc Medtronic 10 percent owner 20 ON HATCH, LOWER HATCH STREET, DUBLIN L2 2
Michael Kaswan officer: Chief Financial Officer KBL HEALTHCARE ACQUISITION CORP II, 645 MADISON AVENUE, NEW YORK NY 10022
Geoffrey Wade Smith director 6740 SHADY OAK ROAD, EDEN PRAIRIE MN 55344
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014